Clearside Biomedical【CLSD】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.9402

買値

0.83

売値

1.05

出来高

179,638

0.93 日の範囲 0.975

0.801 52 週間の範囲 2.12

時価総額

71.308M

前日終値

0.93

始値

0.93

時刻

0.965

最終取引時間

財務取引量

US$ 170,782

VWAP

0.950703

平均取引量 (3 か月)

746,476

発行済株式数

75,843,504

配当利回り

PER

-2.22

1 株当たり利益 (EPS)

-0.43

歳入

8.23M

純利益

-32.49M

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual functio... Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.clearsidebio.com

本社

Wilmington, Delaware, USA

設立

Clearside Biomedical Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker CLSD. The last closing price for Clearside Biomedical was US$0.93. Over the last year, Clearside Biomedical shares have traded in a share price range of US$ 0.801 to US$ 2.12.

Clearside Biomedical currently has 75,843,504 shares in issue. The market capitalisation of Clearside Biomedical is US$70.53 million. Clearside Biomedical has a price to earnings ratio (PE ratio) of -2.22.

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting...

Form 8-K - Current report

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a...

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside’s Suprachoroidal Space...

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Form 4 - Statement of changes in beneficial ownership of securities

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

- CLS-AX Phase 3 Ready Based on Positive Phase 2b Topline Data in Wet AMD - - Differentiated Profile for CLS-AX Targeting Flexible Dosing Similar to a Biologic with the Potential Extended...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.0202	2.19565217391	0.92	0.96	0.801	575199	0.8930368	CS
4	-0.1198	-11.3018867925	1.06	1.11	0.801	325938	0.96666023	CS
12	-0.3798	-28.7727272727	1.32	1.65	0.801	746476	1.21156722	CS
26	-0.2798	-22.9344262295	1.22	1.65	0.801	488853	1.19686021	CS
52	-0.2098	-18.2434782609	1.15	2.12	0.801	389510	1.29154896	CS
156	-2.0055	-68.0822894388	2.9457	3	0.650101	322040	1.50398847	CS
260	-2.4098	-71.9343283582	3.35	7.73	0.650101	542433	2.9629743	CS

CLSD - Frequently Asked Questions (FAQ)

What is the current Clearside Biomedical share price?

The current share price of Clearside Biomedical is US$ 0.9402

How many Clearside Biomedical shares are in issue?

Clearside Biomedical has 75,843,504 shares in issue

What is the market cap of Clearside Biomedical?

The market capitalisation of Clearside Biomedical is USD 70.53M

What is the 1 year trading range for Clearside Biomedical share price?

Clearside Biomedical has traded in the range of US$ 0.801 to US$ 2.12 during the past year

What is the PE ratio of Clearside Biomedical?

The price to earnings ratio of Clearside Biomedical is -2.22

What is the cash to sales ratio of Clearside Biomedical?

The cash to sales ratio of Clearside Biomedical is 8.76

What is the reporting currency for Clearside Biomedical?

Clearside Biomedical reports financial results in USD

What is the latest annual turnover for Clearside Biomedical?

The latest annual turnover of Clearside Biomedical is USD 8.23M

What is the latest annual profit for Clearside Biomedical?

The latest annual profit of Clearside Biomedical is USD -32.49M

What is the registered address of Clearside Biomedical?

The registered address for Clearside Biomedical is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Clearside Biomedical website address?

The website address for Clearside Biomedical is www.clearsidebio.com

Which industry sector does Clearside Biomedical operate in?

Clearside Biomedical operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
INTZIntrusion Inc	US$ 2.167 (381.56%)	189.59M
AILEiLearningEngines Inc	US$ 0.5932 (267.31%)	563.26M
HUBCWHub Cyber Security Ltd	US$ 0.035 (250.00%)	2.79M
GTIGraphjet Technology	US$ 0.967551 (185.83%)	398.95M
LITMSnow Lake Resources Ltd	US$ 1.61 (82.95%)	131.98M
NEUPNeuphoria Therapeutics Inc	US$ 4.11 (-92.30%)	940.73k
VIRXViracta Therapeutics Inc	US$ 0.16 (-32.49%)	9.47M
PRFXPainReform Ltd	US$ 3.48 (-28.98%)	949.52k
AIREreAlpha Tech Corporation	US$ 2.56 (-28.49%)	8.42M
AVGRAvinger Inc	US$ 0.9721 (-24.05%)	2.16M
AILEiLearningEngines Inc	US$ 0.5932 (267.31%)	563.26M
GTIGraphjet Technology	US$ 0.967551 (185.83%)	398.95M
RGTIRigetti Computing Inc	US$ 17.08 (10.62%)	305.79M
XTIAXTI Aerospace Inc	US$ 0.03935 (-1.63%)	268M
QSIQuantum Si Inc	US$ 3.585 (66.74%)	256.01M

銘柄コード

株価

出来高

AILEiLearningEngines Inc

US$ 0.5932

(267.31%)

563.26M

GTIGraphjet Technology

US$ 0.967551

(185.83%)

398.95M

RGTIRigetti Computing Inc

US$ 17.08

(10.62%)

305.79M

XTIAXTI Aerospace Inc

US$ 0.03935

(-1.63%)

268M

QSIQuantum Si Inc

US$ 3.585

(66.74%)

256.01M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Clearside Biomedical Inc (CLSD) 銘柄情報

Clearside Biomedical Inc (CLSD)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Clearside Biomedical Inc について

CLSD 最新ニュース

CLSD - Frequently Asked Questions (FAQ)

ムーバー

CLSD Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手